Defining the clinical course of multiple sclerosis: The 2013 revisions

Fred D Lublin; Stephen C Reingold; Jeffrey A Cohen; Gary R Cutter; Per Soelberg Sørensen; Alan J Thompson; Jerry S Wolinsky; Laura J Balcer; Brenda Banwell; Frederik Barkhof; Bruce Bebo; Peter A Calabresi; Michel Clanet; Giancarlo Comi; Robert J Fox; Mark S Freedman; Andrew D Goodman; Matilde Inglese; Ludwig Kappos; Bernd C Kieseier; John A Lincoln; Catherine Lubetzki; Aaron E Miller; Xavier Montalban; Paul W O'Connor; John Petkau; Carlo Pozzilli; Richard A Rudick; Maria Pia Sormani; Olaf Stüve; Emmanuelle Waubant; Chris H Polman

doi:10.1212/WNL.0000000000000560

Defining the clinical course of multiple sclerosis: The 2013 revisions

Fred D Lublin, Stephen C Reingold, Jeffrey A Cohen, Gary R Cutter, Per Soelberg Sørensen, Alan J Thompson, Jerry S Wolinsky, Laura J Balcer, Brenda Banwell, Frederik Barkhof, Bruce Bebo, Peter A Calabresi, Michel Clanet, Giancarlo Comi, Robert J Fox, Mark S Freedman, Andrew D Goodman, Matilde Inglese, Ludwig Kappos, Bernd C KieseierJohn A Lincoln, Catherine Lubetzki, Aaron E Miller, Xavier Montalban, Paul W O'Connor, John Petkau, Carlo Pozzilli, Richard A Rudick, Maria Pia Sormani, Olaf Stüve, Emmanuelle Waubant, Chris H Polman

Department of Clinical Medicine

1309 Citations (Scopus)

Abstract

Accurate clinical course descriptions (phenotypes) of multiple sclerosis (MS) are important for communication, prognostication, design and recruitment of clinical trials, and treatment decision-making. Standardized descriptions published in 1996 based on a survey of international MS experts provided purely clinical phenotypes based on data and consensus at that time, but imaging and biological correlates were lacking. Increased understanding of MS and its pathology, coupled with general concern that the original descriptors may not adequately reflect more recently identified clinical aspects of the disease, prompted a re-examination of MS disease phenotypes by the International Advisory Committee on Clinical Trials of MS. While imaging and biological markers that might provide objective criteria for separating clinical phenotypes are lacking, we propose refined descriptors that include consideration of disease activity (based on clinical relapse rate and imaging findings) and disease progression. Strategies for future research to better define phenotypes are also outlined.

Original language	English
Journal	Neurology
Volume	83
Issue number	3
Pages (from-to)	278-286
Number of pages	9
ISSN	0028-3878
DOIs	https://doi.org/10.1212/WNL.0000000000000560
Publication status	Published - 15 Jul 2014

Keywords

Clinical Trials as Topic
Consensus
Humans
Multiple Sclerosis
Societies, Medical

Access to Document

10.1212/WNL.0000000000000560

Cite this

Lublin, F. D., Reingold, S. C., Cohen, J. A., Cutter, G. R., Sørensen, P. S., Thompson, A. J., Wolinsky, J. S., Balcer, L. J., Banwell, B., Barkhof, F., Bebo, B., Calabresi, P. A., Clanet, M., Comi, G., Fox, R. J., Freedman, M. S., Goodman, A. D., Inglese, M., Kappos, L., ... Polman, C. H. (2014). Defining the clinical course of multiple sclerosis: The 2013 revisions. Neurology, 83(3), 278-286. https://doi.org/10.1212/WNL.0000000000000560

Lublin, FD, Reingold, SC, Cohen, JA, Cutter, GR, Sørensen, PS, Thompson, AJ, Wolinsky, JS, Balcer, LJ, Banwell, B, Barkhof, F, Bebo, B, Calabresi, PA, Clanet, M, Comi, G, Fox, RJ, Freedman, MS, Goodman, AD, Inglese, M, Kappos, L, Kieseier, BC, Lincoln, JA, Lubetzki, C, Miller, AE, Montalban, X, O'Connor, PW, Petkau, J, Pozzilli, C, Rudick, RA, Sormani, MP, Stüve, O, Waubant, E & Polman, CH 2014, 'Defining the clinical course of multiple sclerosis: The 2013 revisions', Neurology, vol. 83, no. 3, pp. 278-286. https://doi.org/10.1212/WNL.0000000000000560

@article{f051d4c1f2b341d2906ee5fd9df90885,

title = "Defining the clinical course of multiple sclerosis: The 2013 revisions",

abstract = "Accurate clinical course descriptions (phenotypes) of multiple sclerosis (MS) are important for communication, prognostication, design and recruitment of clinical trials, and treatment decision-making. Standardized descriptions published in 1996 based on a survey of international MS experts provided purely clinical phenotypes based on data and consensus at that time, but imaging and biological correlates were lacking. Increased understanding of MS and its pathology, coupled with general concern that the original descriptors may not adequately reflect more recently identified clinical aspects of the disease, prompted a re-examination of MS disease phenotypes by the International Advisory Committee on Clinical Trials of MS. While imaging and biological markers that might provide objective criteria for separating clinical phenotypes are lacking, we propose refined descriptors that include consideration of disease activity (based on clinical relapse rate and imaging findings) and disease progression. Strategies for future research to better define phenotypes are also outlined.",

keywords = "Clinical Trials as Topic, Consensus, Humans, Multiple Sclerosis, Societies, Medical",

author = "Lublin, {Fred D} and Reingold, {Stephen C} and Cohen, {Jeffrey A} and Cutter, {Gary R} and S{\o}rensen, {Per Soelberg} and Thompson, {Alan J} and Wolinsky, {Jerry S} and Balcer, {Laura J} and Brenda Banwell and Frederik Barkhof and Bruce Bebo and Calabresi, {Peter A} and Michel Clanet and Giancarlo Comi and Fox, {Robert J} and Freedman, {Mark S} and Goodman, {Andrew D} and Matilde Inglese and Ludwig Kappos and Kieseier, {Bernd C} and Lincoln, {John A} and Catherine Lubetzki and Miller, {Aaron E} and Xavier Montalban and O'Connor, {Paul W} and John Petkau and Carlo Pozzilli and Rudick, {Richard A} and Sormani, {Maria Pia} and Olaf St{\"u}ve and Emmanuelle Waubant and Polman, {Chris H}",

note = "{\textcopyright} 2014 American Academy of Neurology.",

year = "2014",

month = jul,

day = "15",

doi = "10.1212/WNL.0000000000000560",

language = "English",

volume = "83",

pages = "278--286",

journal = "Neurology",

issn = "0028-3878",

publisher = "Lippincott Williams & Wilkins",

number = "3",

}

TY - JOUR

T1 - Defining the clinical course of multiple sclerosis

T2 - The 2013 revisions

AU - Lublin, Fred D

AU - Reingold, Stephen C

AU - Cohen, Jeffrey A

AU - Cutter, Gary R

AU - Sørensen, Per Soelberg

AU - Thompson, Alan J

AU - Wolinsky, Jerry S

AU - Balcer, Laura J

AU - Banwell, Brenda

AU - Barkhof, Frederik

AU - Bebo, Bruce

AU - Calabresi, Peter A

AU - Clanet, Michel

AU - Comi, Giancarlo

AU - Fox, Robert J

AU - Freedman, Mark S

AU - Goodman, Andrew D

AU - Inglese, Matilde

AU - Kappos, Ludwig

AU - Kieseier, Bernd C

AU - Lincoln, John A

AU - Lubetzki, Catherine

AU - Miller, Aaron E

AU - Montalban, Xavier

AU - O'Connor, Paul W

AU - Petkau, John

AU - Pozzilli, Carlo

AU - Rudick, Richard A

AU - Sormani, Maria Pia

AU - Stüve, Olaf

AU - Waubant, Emmanuelle

AU - Polman, Chris H

PY - 2014/7/15

Y1 - 2014/7/15

N2 - Accurate clinical course descriptions (phenotypes) of multiple sclerosis (MS) are important for communication, prognostication, design and recruitment of clinical trials, and treatment decision-making. Standardized descriptions published in 1996 based on a survey of international MS experts provided purely clinical phenotypes based on data and consensus at that time, but imaging and biological correlates were lacking. Increased understanding of MS and its pathology, coupled with general concern that the original descriptors may not adequately reflect more recently identified clinical aspects of the disease, prompted a re-examination of MS disease phenotypes by the International Advisory Committee on Clinical Trials of MS. While imaging and biological markers that might provide objective criteria for separating clinical phenotypes are lacking, we propose refined descriptors that include consideration of disease activity (based on clinical relapse rate and imaging findings) and disease progression. Strategies for future research to better define phenotypes are also outlined.

AB - Accurate clinical course descriptions (phenotypes) of multiple sclerosis (MS) are important for communication, prognostication, design and recruitment of clinical trials, and treatment decision-making. Standardized descriptions published in 1996 based on a survey of international MS experts provided purely clinical phenotypes based on data and consensus at that time, but imaging and biological correlates were lacking. Increased understanding of MS and its pathology, coupled with general concern that the original descriptors may not adequately reflect more recently identified clinical aspects of the disease, prompted a re-examination of MS disease phenotypes by the International Advisory Committee on Clinical Trials of MS. While imaging and biological markers that might provide objective criteria for separating clinical phenotypes are lacking, we propose refined descriptors that include consideration of disease activity (based on clinical relapse rate and imaging findings) and disease progression. Strategies for future research to better define phenotypes are also outlined.

KW - Clinical Trials as Topic

KW - Consensus

KW - Humans

KW - Multiple Sclerosis

KW - Societies, Medical

U2 - 10.1212/WNL.0000000000000560

DO - 10.1212/WNL.0000000000000560

M3 - Review

C2 - 24871874

SN - 0028-3878

VL - 83

SP - 278

EP - 286

JO - Neurology

JF - Neurology

IS - 3

ER -

Defining the clinical course of multiple sclerosis: The 2013 revisions

Abstract

Keywords

Access to Document

Fingerprint

Cite this